Long-acting protein drugs for the treatment of ocular diseases

Protein drugs that neutralize vascular endothelial growth factor (VEGF), such as aflibercept or ranibizumab, rescue vision in patients with retinal vascular diseases. Nonetheless, optimal visual outcomes require intraocular injections as frequently as every month. Here we report a method to extend t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Joy G., Nguyen, Andrew A., Bigelow, Chad E., Poor, Stephen, Qiu, Yubin, Rangaswamy, Nalini, Ornberg, Richard, Jackson, Brittany, Mak, Howard, Ezell, Tucker, Kenanova, Vania, de la Cruz, Elisa, Carrion, Ana, Etemad-Gilbertson, Bijan, Caro, Roxana Garcia, Zhu, Kan, George, Vinney, Bai, Jirong, Sharma-Nahar, Radhika, Shen, Siyuan, Wang, Yiqin, Subramanian, Kulandayan K., Fassbender, Elizabeth, Maker, Michael, Hanks, Shawn, Vrouvlianis, Joanna, Leehy, Barrett, Long, Debby, Prentiss, Melissa, Kansara, Viral, Jaffee, Bruce, Dryja, Thaddeus P., Roguska, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376645/
https://www.ncbi.nlm.nih.gov/pubmed/28332616
http://dx.doi.org/10.1038/ncomms14837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376645/
https://www.ncbi.nlm.nih.gov/pubmed/28332616
http://dx.doi.org/10.1038/ncomms14837

Ejemplares similares